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Abstract
Background: There is a long-lasting need for non-invasive, more accurate diagnostic techniques when evaluating
primary Sjögren’s syndrome (pSS) patients. Incorporation of additional diagnostics involving screening for
disease-specific biomarkers in biological fluid is a promising concept that requires further investigation.
In the current study we aimed to explore novel disease biomarkers in saliva and tears from pSS patients.
Methods: Liquid chromatography-mass spectrometry (LC-MS) was performed on stimulated whole saliva and tears
from 27 pSS patients and 32 healthy controls, and salivary and tear proteomic biomarker profiles were generated.
LC-MS was also combined with size exclusion chromatography to isolate extracellular vesicles (EVs) from both fluids.
Nanoparticle tracking analysis was conducted on joint fractions from the saliva and tears to determine size
distribution and concentration of EVs. Further EV characterisation was performed by immunoaffinity capture of
CD9-positive EVs using magnetic beads, detected by flow cytometry. The LC-MS data were analysed for quantitative
differences between patient and control groups using Scaffold, and the proteins were further analysed using the
Database for Annotation, Visualization and Integrated Discovery (DAVID), for gene ontology overrepresentation,
and the Search Tool for the Retrieval of Interacting Genes/Proteins for protein-protein interaction network analysis.
Results: Upregulation of proteins involved in innate immunity (LCN2), cell signalling (CALM) and wound repair
(GRN and CALML5) were detected in saliva in pSS. Saliva EVs also displayed biomarkers critical for activation of the
innate immune system (SIRPA and LSP1) and adipocyte differentiation (APMAP). Tear analysis indicated
overexpression of proteins involved in TNF-α signalling (CPNE1) and B cell survival (PRDX3). Moreover, neutrophil
gelatinase-associated lipocalin was upregulated in saliva and tears in pSS. Consistently, DAVID analysis
demonstrated pathways of the adaptive immune response in saliva, of cellular component assembly for saliva EVs,
and of metabolism and protein folding in tears in pSS patients.
Conclusions: LC-MS of saliva and tears from pSS patients, solely and in combination with size-exclusion chromatography
allowed screening for possible novel biomarkers encompassing both salivary and lacrimal disease target organs. This
approach could provide additional diagnostic accuracy in pSS, and could possibly also be applied for staging and
monitoring the disease.
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Background
Sjögren’s syndrome (SS) is a systemic rheumatic auto-
immune disease, where chronic inflammation results in
progressive destruction of exocrine glands, primarily the
lacrimal and salivary glands [1, 2]. Thus, characteristic
features are sicca symptoms, including dry eyes and dry
mouth [3]. The prevalence of SS has been reported to be
between 0.01% and 0.6% [4–6].
The main classification criteria used today when diagnos-
ing primary SS (pSS) are the American-European Consen-
sus Group (AECG) criteria from 2002 [7], which rely on
evaluating symptoms of ocular and oral dryness, assessing
the secretory ability of the exocrine glands, screening for
anti-Ro and anti-La autoantibodies, and evaluating biopsies
of minor salivary glands for mononuclear cell infiltration
[8]. This routine assessment of minor salivary gland tissue
and histological focus scoring has been employed to
describe salivary gland involvement in SS [9, 10]. Here, a
positive biopsy with mononuclear cell infiltrates compris-
ing ≥50 mononuclear cells per 4 mm2 resulted in a positive
focus score value ranging from 1 to 12 according to the
number of foci seen. This is a semi-quantitative, invasive
technique useful for patients with glandular dysfunctions
without autoantibody production [11].
Considering the nature of the currently available diagnos-
tic tools, there remains an unmet need for non-invasive,
more accurate diagnosis of pSS. The incorporation of
additional non-invasive diagnostics, such as screening for
disease-specific biomarkers [12, 13] has therefore been in
focus over recent decades, as it can also be applied for
staging and monitoring of the disease. Indeed, liquid
chromatography-mass spectrometry (LC-MS) has been
applied in several human rheumatic diseases, including SS,
in order to discover biomarkers and therapeutic targets by
studying the proteome of biological fluids [14, 15]. Both sal-
iva [14, 16–21] and tear fluid [22, 23] have previously been
used to identify potential biomarkers for SS. It has been re-
ported that oral fluid not only reflects the salivary gland in-
volvement that characterises SS disease [18, 24, 25], but also
has the potential to represent the subject’s current general
health [26, 27]. Moreover, salivary fluid samples can easily
be obtained using a non-invasive, simple, safe, and stress-
free procedure, allowing for repetition and multiple collec-
tions. This explains why the majority of proteomic studies
of SS have chosen saliva as the ideal biological fluid, exam-
ining either whole saliva or saliva from individual glands
(e.g. minor and/or parotid salivary glands), under both
stimulated and unstimulated conditions [14, 16–21]. As a
result, several common biomarkers for SS have been found,
including secretory proteins, enzymes, highly abundant
immune-system-related molecules (e.g. β2-microglobulin),
and cytokines such as IL-4 and IL-5 [21, 28, 29].
Proteomic analyses can also be coupled with various separ-
ation techniques in order to isolate the cellular components
of interest when screening for disease biomarkers. Extracel-
lular vesicles (EVs) are an example of such cellular compo-
nents. These are membrane-embedded vesicles, comprising
exosomes (size <100 nm) and/or microvesicles (size 100–
1000 nm) [30], released by cells that are emerging as import-
ant mediators of intercellular communication, and thereby
influencing recipient cell functions [31–33]. For instance,
EVs can act on the innate immune system as paracrine
messengers and have been described as pro-inflammatory
mediators that induce inflammatory signals during infections
[34, 35] and chronic inflammatory diseases [35].
Interestingly, patients with autoimmune diseases have
increased levels of EVs that carry components associated
with complement activation [36, 37]. Accordingly, various
cell types of the innate immune system are known to release
EVs, including macrophages [38], monocytes or dendritic
cells [39] and natural killer (NK) cells [40]. Besides mediat-
ing the exchange of intercellular information by their surface
molecules, EVs have been shown to be carriers of important
soluble mediators, such as cytokines. The involvement of
EVs in the transport of the cytokines IL-1b [41] and tumour
necrosis factor (TNF) [42] are such examples.
Proteomic profiling of EVs in a biological context can be
challenging, especially if the EV preparations are not highly
purified [43]. In complex body fluids, EVs can be separated
from interfering molecules, such as proteins and lipids, by
utilising size-exclusion chromatography [44, 45]. The
isolated sub-fractions containing the highest EV concentra-
tions can then be characterised using nanoparticle tracking
analysis, and by flow cytometry detection of the fusogenic
protein/tetraspanin CD9, which is abundantly expressed in
EVs [46–48].
Proteomic studies of isolated EVs have in turn yielded
extensive catalogues that display which proteins are
abundant in different types of EVs, specifically reflecting
vesicle localization, cellular origin, and mechanism of secre-
tion [49]. Hence, in the current study we hypothesised that
by applying LC-MS alone, and in combination with EV-
isolation, using samples of stimulated whole saliva and tear
fluid from patients with pSS and healthy controls, novel
biomarkers may be identified encompassing both salivary
and lacrimal disease target organs. Such biomarkers may in
turn be implemented, as potential non-invasive diagnostic
tools that can help to increase diagnostic accuracy when
evaluating patients with pSS, in accordance with the AECG




Patients with pSS (n = 27) that fulfilled the AECG classifica-
tion criteria from 2002 [7] and 32 age-matched and gender-
matched controls participated in this study. Following
recruitment at the Department of Rheumatology, Oslo
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University Hospital, the patients were referred to the Dry
Mouth Clinic, located at the Institute of Clinical Dentistry,
Faculty of Dentistry, University of Oslo, and the Norwegian
Dry Eye Clinic, Oslo, for thorough examination and sample
collection, as described below. A detailed explanation of the
study aim and protocols were explained to the recruited
subjects upon enrolment. Written informed consent was
obtained from the participants and the Regional Medical
Ethical Committee of South-East Norway approved the
study (2015/363).
Medical records and clinical data were obtained through
clinical examination and from patients’ charts at the De-
partment of Rheumatology, Oslo University Hospital. This
provided information that had been collected during rou-
tine laboratory assessments, including anti-Ro/SSA and
anti-La/SSB, and evaluation of ocular and oral dryness by
assessing saliva and tear secretion. Some residual secretory
ability was required for inclusion of the patients in the
study. The demographic data for the patients included in
this study are presented in Table 1.
Saliva and tear fluid collection
Saliva collection at the Dry Mouth Clinic
Participants underwent a thorough oral examination at the
Dry Mouth Clinic, and stimulated whole saliva was col-
lected from all participants. Subjects were asked to not have
any food or drink for at least 1 hour before saliva collection.
Following the oral examination, the participants were asked
to chew on a paraffin block (Paraffin Pellets, Ivoclor Viva-
dent, Shaen, Lichtenstein), while saliva was collected on ice
for 5 minutes between 9.00 a.m. and 3.00 p.m. As secretory
ability has been shown to vary depending on stimulation by
chewing, and on the time of day, these strict routines were
employed to ensure standardisation of the method for saliva
collection. The samples were weighed to determine volume,
where only patients producing ≥800 μl of stimulated whole
saliva were included in the study. All samples were then ali-
quoted and stored at -80 °C.
Tear fluid collection at the Norwegian Dry Eye Clinic
Participants underwent a thorough ocular surface exam-
ination at the Norwegian Dry Eye Clinic. Tear fluid was
collected from both eyes by placing a Schirmer tear test
strip (HAAG-STREIT, Essex, UK) on each eye for 5 mi-
nutes, or more to produce a minimum combined total
of 10 mm of tear volume from both eyes at room
temperature. Each Schirmer strip was then transferred
to 500 μl of 0.1 μm filtered phosphate-buffered saline
(PBS) (Gibco, pH 7.4, ThermoFisher Scientific, Oslo,
Norway) and stored at -80 °C.
Extraction of EVs from saliva
EVs were isolated from stimulated whole saliva using
size-exclusion chromatography, as described previously
[44]. In brief, the saliva samples were centrifuged at
300 rpm for 10 minutes to remove debris, and then di-
luted 1:2 with 0.1 μm filtered PBS. A qEV size-exclusion
chromatography column (iZON Science, Oxford, UK)
was equilibrated by washing the column with 15 ml of
0.1 μm filtered PBS; 1 ml of the diluted saliva was then
applied to the column and 16 fractions, each 500 μl in
volume, were collected by continuously adding 0.1 μm
filtered PBS to the column. To standardise the proced-
ure, elution time frames were recorded when reaching
fractions 7, 12 and 15, and the number of eluted drops
in fraction 10 was also recorded. A new column was
used for each saliva sample. The eluted fractions 8 − 10
(containing the majority of microvesicles and exosomes


















PSS1 69 + - + + + +
PSS2 41 + + - + + +
pSS3 64 + - - + + +
pSS4 33 + - + + + -
pSS5 57 + + + + + +
pSS6 55 + + + + + +
pSS7 69 + + + + + +
pSS8 40 + + + + + +
pSS9 64 + + + + + +
pSS10 72 + + + + + +
pSS11 54 + - + + + +
pSS12 36 + - + + + +
pSS13 53 + - + + + +
pSS14 47 + + + + + +
pSS15 73 + - + - + +
pSS16 54 + + + + + +
pSS17 33 + + + + + +
pSS18 69 + + + + + +
pSS19 51 + - + - + +
pSS20 48 + + + + + +
pSS21a 48 + + + + + +
pSS22a 44 + + + + + +
pSS23a 40 + + + + + +
pSS24a 47 + + + + + +
pSS25a 64 + + + + + +
pSS26a 39 + + + + + +
pSS27a 51 + + + + + +
aPatients with pSS included in pooled tear sample only. bAutoantibody
production was assessed by ELISA. cValues are in mm/5 minutes; normal flow
>5 mm/5 minutes. The + symbol indicates dryness and tear secretion <5 mm/
5 minutes. dValues are in ml/15 minutes; normal flow >1.5 ml/15. The + symbol
indicates dryness and stimulated whole saliva secretion <3.5 ml/5 minutes
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present in the samples) were concentrated for 80 minutes
at 30 °C in a MiVac centrifugal vacuum concentrator (SP
Scientific, Suffolk, UK) from a volume of 500 μl to
approximately 250 μl. Fractions 8–10 were collected into
a joint fraction and the protein concentration was deter-
mined using Qubit Fluorometric Quantitation (Thermo-
Fisher Scientific, Oslo, Norway). A volume of the diluted
stimulated whole saliva (100 μl) and the joint fractions
from each participant were then sent for proteomic ana-
lysis while preserved on dry ice.
Extraction of EVs from tear fluid
For each subject, tear fluid eluted from Schirmer strips into
0.1 μm filtered PBS (1 ml; pooling of 500 μl PBS containing
a Schirmer strip from each eye) was applied to an equili-
brated qEV size exclusion chromatography column. Frac-
tions of 500 μl were eluted and concentrated, and fractions
8–10 were collected into a joint fraction and the protein
concentration was determined as described above. A new
column was used for each sample. Due to the low numbers
of proteins and vesicles in tear fluid collected from the indi-
vidual patients with pSS (minimum 10 mm fluid per pa-
tient), tear fluid from Schirmer strips containing 80 mm
tear fluid from 11 patients with pSS was pooled in 5 ml
PBS. The pooled sample was subsequently concentrated to
200 μl using Amicon Ultra-4 columns and furthermore
adjusted to a volume 1.0 ml with PBS before being applied
on a qEV column. Schirmer strips also containing 80 mm
tear fluid from five controls were handled in parallel. These
pooled tear fluid samples were included for verification. A
small volume from the tear fluid sample of each participant
(100 μl), the joint fractions from each individual, and the
joint fractions from pooled tear samples of the patients with
pSS and the controls were then sent for proteomic analysis
while preserved on dry ice.
Characterisation of EVs
Nanoparticle tracking analysis
Nanoparticle tracking analysis was conducted on joint
fractions from saliva and tear fluid to determine size
distribution and concentration of the respective EVs using
a NanoSight NS500 instrument (Malvern Instruments
Ltd, Malvern, UK), equipped with a scientific cMOS
camera with trigger, a 488-nm laser, and a syringe pump
for continuous sample flow. Samples were diluted in
0.02 μm filtered PBS to reach the measurement range
(108 − 109 particles/ml). Analysis was performed using the
NTA 3.0 software (Malvern Instruments, Malvern, UK).
Briefly, a video capture of 60 seconds per sample was ap-
plied. The camera level was set to 14–15 for saliva and
12–15 for tear fractions, and the detection threshold was
set to 3. The hydrodynamic diameter of the particles in
each sample was calculated by the software, through regis-
tering their Brownian motion in response to laser light
scattering, utilising the Stokes Einstein equation. Sample
concentration was estimated as a subsequent parameter of
the sample volume. A summary of the measurements ob-
tained from the nanoparticle tracking analysis for EV char-
acterisation in saliva and tear fluid is presented in Table 2.
Flow cytometry detection of CD9 positive EVs
Immunoaffinity capture and detection of CD9 positive
EVs from joint fractions was performed using the Exo-
some Human CD9 Flow Detection Kit (Dynal®, Thermo-
Fisher Scientific, Oslo, Norway) and flow cytometry. In
brief, 100 μl of each joint fraction was incubated overnight
with prewashed 20 μl Dynabeads (2.7 mm) on a Hula-
Mixer Sample mixer at 4 °C. The bead-captured EVs were
then washed three times with 0.1 μm filtered PBS contain-
ing 0.1% bovine serum albumin (BSA). Subsequently, they
were incubated with RPE-conjugated detection antibody
(anti-human CD9-RPE clone ML-13, BD Biosciences,
Oslo, Norway), or isotype control (IgG1-RPE, BD Biosci-
ences, Oslo, Norway), for 45 minutes at room temperature
on an orbital shaker (1000 rpm), protected from light. The
bead-containing samples were further washed twice with
PBS containing 0.1% BSA before proceeding with flow
cytometry analysis, using a BD Accuri™ C6 Cytometer (BD
Biosciences, Oslo, Norway). Median fluorescence intensity
(MFI) was reported as a signal to noise (S/N) ratio to
isotype control from a total of 300 singlet events.
Measurements obtained from the flow cytometry analyses








189 ± 4.1 5.46 E + 10 ± 1.43 E + 10* 3.47 ± 0.56*




171 ± 6.9 1.54 E + 09 ± 3.08 E + 08 1.10 ± 0.03




190 2.04 E + 10 2.88
Pool of
controls
144 8.45 E + 09 1.06
aNanoparticle tracking analysis was conducted on extracellular vesicles (EV)
joint fractions from whole saliva (n = 19 patients with primary Sjögren’s
syndrome (pSS), n = 32 controls), tear fluid (n = 7 patients with pSS, n = 6
controls), and one pooled tear sample (n = 11 patients with pSS, n = 5 controls)
to determine mean particle size of microvesicles and exosomes (nm ± SEM), in
addition to concentrations of EVs (particles/ml ± SEM).bDetection of CD9+ EVs
from joint fractions of saliva (n = 19 patients with pSS, n = 32 controls), tear
fluid (n = 11 patients with pSS, n = 10 controls), and one pooled tear sample
(n = 11 patients with pSS, n = 5 controls) was performed by immunoaffinity
capture using anti-CD9-coated magnetic beads followed by flow cytometry
analysis. The results were reported as signal-to-noise (S/N) ratios of median
fluorescence intensity (MFI). *Significant difference between patients with pSS
and controls (unpaired t test, p < 0.05)
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for EV characterisation in saliva and tear fluid are pre-
sented in Table 2.
Determination of protein amount
Proteomics analysis was executed on saliva and tear fluid
from both patients with pSS and controls before and after
isolation of EVs. Total protein concentration (mg/ml) in
the saliva samples ranged from 0.5 to 1.36 in patients with
pSS, and from 0.25 to 0.94 in controls. Meanwhile, saliva
joint fractions showed a total protein range of 0.04 to 0.07
in patients with pSS, and 0.02 to 0.07 in controls. The total
protein concentration in tear samples ranged from 0.27 to
0.70 in patients with pSS, while in controls this ranged from
0.22 to 0.70. Tear joint fractions displayed a total protein
range from 0.03 to 0.05 in patients with pSS, and 0.03 to
0.04 in controls. The total protein in the pooled tear sample
was 0.47 mg/ml in the patients with pSS and 0.35 mg/ml in
the controls. Additionally, the joint fractions in the pooled
tear sample exhibited a total protein value of 0.03 mg/ml in
the patients with pSS, and 0.03 mg/ml in the controls.
In-solution protein digestion
For saliva and EVs of saliva, four times the sample volume
of ice-cold acetone was added to each sample, vortexed and
precipitated overnight at -20 °C. Samples were then centri-
fuged at 16,000 g for 20 minutes at 4 °C (Centrifuge 5415R,
Eppendorf, Hamburg, Germany) and the supernatants were
discarded. Proteins were re-dissolved in 50 μl of a mixture
of 6 M urea and 100 mM ammonium bicarbonate (pH 7.8).
For reduction and alkylation of cysteines, 2.5 μl of 200 mM
DTT in 100 mM Tris-HCl (pH 8) was added and the sam-
ples were incubated at 37 °C for 1 hour followed by the
addition of 7.5 μl of 200 mM iodoacetamide for 1 hour at
room temperature in the dark. The alkylation reaction was
quenched by adding 10 μl of 200 mM DTT at 37 °C for
1 hour. For all samples, the proteins were digested with
10 μg of trypsin for 16 hours at 37 °C. The digestion was
stopped by adding 5 μl of 50% formic acid. The generated
peptides were purified using an OMIX C18-micro SPE
(Agilent, Santa Clara, CA, USA), and then dried using a
Speed Vac concentrator (Concentrator Plus, Eppendorf,
Hamburg, Germany).
Liquid LC-MS
The tryptic peptides were dissolved in 10 μl of 0.1% formic
acid/2% acetonitrile, and 5 mμl was analysed using an
Ultimate 3000 RSLCnano-UHPLC system connected to a Q
Exactive mass spectrometer (Thermo Fisher Scientific, Bre-
men, Germany), and also equipped with a nano electrospray
ion source. For liquid chromatography separation, an Ac-
claim PepMap 100 column was used (C18, 2 μm beads,
100 Å, 75 μm inner diameter, 50 cm length) (Dionex,
Sunnyvale CA, USA). A flow rate of 300 nl/minute was
employed with a solvent gradient of 4 − 35% B in 47 minutes,
to 50% B in 3 minutes and then to 80% B in 2 minutes.
Solvent A was 0.1% formic acid and solvent B was 0.1%
formic acid/90% acetonitrile.
The mass spectrometer was operated in the data-
dependent mode to automatically switch between MS and
MS/MS acquisition. Survey full-scan MS spectra (from m/z
300 to 2,000) were acquired with the resolution R = 70 000
at m/z 200, after accumulation to a target of 1e6. The max-
imum allowed ion accumulation time was 60 milliseconds.
The method used allowed sequential isolation of up to the
ten most intense ions, depending on signal intensity (inten-
sity threshold 1.7e4), for fragmentation using higher-energy
collisional-induced dissociation (HCD) at a target value of
10,000 charges, and a resolution R = 17,500. Target ions
already selected for MS/MS were dynamically excluded for
60 seconds. The isolation window was m/z = 2 without off-
set. For accurate mass measurements, the lock mass option
was enabled in MS mode.
Data were acquired using Xcalibur v2.5.5 and raw files
were processed to generate peak list in Mascot generic
format (*.mgf) using ProteoWizard release version
3.0.331. Database searches were performed using Mascot
in-house version 2.4.0 to search the SwissProt database
(Human, 20,279 proteins) assuming the digestion enzyme
trypsin, at maximum of one missed cleavage site, fragment
ion mass tolerance of 0.05 Da, parent ion tolerance of
10 ppm, and oxidation of methionines, and acetylation of
the protein N-terminus as variable modifications. For
saliva and EVs of saliva, carbamidomethylation of cyste-
ines as fixed modification was used in addition.
Data processing and statistical analysis
Scaffold (version Scaffold_4.4, Proteome Software Inc.,
Portland, OR, USA) was used to validate MS/MS-based
peptide and protein identifications. Peptide identifications
were accepted if they could be established at greater than
95.0% probability by the Scaffold Local false discovery rate
(FDR) algorithm. Protein identifications were accepted if
they could be established at greater than 99.0% probability.
For label-free quantification, the entire MS2 total ion
current (TIC) across all biological replicates was evaluated
using the t test. For functional analysis of the proteomics
data, the Search Tool for the Retrieval of Interacting Genes/
Proteins) (STRING) (http://string-db.org/) and the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) (v 6.7, https://david.ncifcrf.gov) were applied. Stim-
ulated whole saliva, saliva EVs (joint fractions) and tear fluid
were analysed individually, comparing the 10 patients with
pSS and controls with the highest number of proteins.
STRING was used to explore how these proteins were inter-
related to form protein-protein interaction networks, by
applying all active interaction sources (experiments, data-
bases and text mining), and medium confidence. Further-
more, DAVID was applied, using an FDR with a maximum
Aqrawi et al. Arthritis Research & Therapy  (2017) 19:14 Page 5 of 15
5% cutoff, in order to delineate specific cellular pathways in-
volving these upregulated proteins in the patients with pSS.
The unregulated group of proteins was also examined and
compared to the DAVID analysis for each of stimulated
whole saliva, saliva EVs (joint fractions) and tear samples.
Results
Workflow for the identification of proteins upregulated in
patients with pSS
The proteome of saliva, tear fluid, and EVs of both saliva
and tear fluid from patients and controls were examined
by digestion of the proteins with trypsin, analysis of the
proteins by LC-MS, identification of the proteins using
Mascot database searches and further data analysis using
Scaffold to find quantitative differences based on the t test
applied on MS2 total ion currents. Significantly upregu-
lated proteins with p values <0.05 according to the t test
were further analysed using DAVID for gene ontology
(GO) term overrepresentation and STRING for protein-
protein network analysis.
Upregulation of proteins involved in innate immunity, cell
signalling and wound repair in whole saliva from patients
with pSS
LC-MS analysis of whole saliva from 20 patients and 32
healthy controls identified approximately 500 unique pro-
teins with 48,424 peptide spectrum matches. Thirty-eight
proteins were upregulated in whole saliva in the pSS patient
group compared to the controls (Scaffold: t test, p < 0.05)
(Additional file 1: Table S1).
GO overrepresentation analysis using DAVID indicated
that cellular pathways for the upregulated proteins in the
whole saliva from the pSS patient group, in comparison to
unregulated proteins, included lymphocyte-mediated im-
munity, calcium ion binding and the neutrophin signalling
pathway. These pathways are all components of the adap-
tive immune response (Fig. 1).
The STRING analysis revealed that the upregulated
proteins in whole saliva from patients with pSS formed two
distinct protein-protein interaction networks; one is in-
volved in metabolism and redox reactions, while the other
plays a central role in both innate and adaptive immunity
(Fig. 2). Assuming proteins found only in the pSS patient
group would be the most promising candidates for poten-
tial disease biomarkers, we also considered the number of
biological replicates in our analyses. Accordingly, the five
most deviating upregulated proteins considering biological
replicates and spectral counts were neutrophil gelatinase-
associated lipocalin (LCN2), granulins (GRN), calmodulin
(CALM), epididymal secretory protein 1 (NPC2), and
calmodulin-like protein 5 (CALML5), in descending order
(Table 3, Additional file 2: Figure S1). The most upregulated
protein in whole saliva from patients with pSS, namely
LCN2, is an iron-binding protein involved in apoptosis and
the innate immune system, and is particularly responsible
for the activation of neutrophils. It is also an indicator of
acute renal failure. LCN2 is therefore present within the
protein network involved in both innate and adaptive im-
munity (Fig. 2). GRN is a cytokine-like peptide that is cen-
tral in inflammation due to its active role in wound repair
and tissue remodelling. CALM and CALML5 are calcium-
binding proteins and play a role in intracellular signalling
and differentiation of keratinocytes, respectively. ESP1 is a
cholesterol transporter involved in cholesterol homeostasis
within the endosome and/or lysosome (Table 3).
EVs in whole saliva from patients with pSS express
abundant proteins vital for activation of the innate
immune system and adipocyte differentiation
LC-MS analysis of EVs from whole saliva from 20 patients
and 32 healthy controls identified around 500 unique pro-
teins with 48,620 peptide spectrum matches. Thirty six pro-
teins were significantly upregulated in patients with pSS
compared to controls (Scaffold, t test, p < 0.05) (Additional
file 1: Table S2).
The DAVID analysis of EVs from whole saliva revealed
cellular pathways involved in adhesion, cytoskeleton or-
ganisation and membrane fusion. Together, these path-
ways are involved in cellular component assembly, and
possess the most significantly changed GO terms when
compared with the identified unregulated proteins (Fig. 1).
One major protein-protein interacting network was iden-
tified for the upregulated proteins in EVs isolated from
whole saliva from patients with pSS. This observation was
visualised using STRING analysis (Fig. 3). These proteins
are active players in the cytoskeleton, and are also involved
in cell migration and cell junction. The five upregulated
proteins that deviated most in biological replicates between
patients with pSS and controls and that were detected in
EVs from whole saliva were adipocyte plasma membrane-
associated protein (APMAP), guanine nucleotide-binding
protein subunit alpha-13 (GNA13), WD repeat-containing
protein 1 (WDR1), tyrosine-protein phosphatase non-
receptor type substrate 1 (SIRPA), and lymphocyte-specific
protein 1 (LSP1) (Table 4, Additional file 3: Figure S2).
The most changed of these proteins in EVs from whole
saliva, APMAP, is an enzyme central in adipocyte differenti-
ation. Moreover, GNA13 is a G-protein that consequently
plays a role in transmembrane signalling, while WDR1 is a
regulatory protein involved in the disassembly of actin
filaments. Interestingly, SIRPA is a glycoprotein present in
innate immunity, particularly in the regulation of NK cells
and dendritic cell inhibition. LSP1 is an actin-binding pro-
tein also involved in innate immunity, specifically neutro-
phil activation, and chemotaxis (Table 4). Out of the five
most upregulated proteins; both GNA13 and WDR1 are
present within the protein network identified (Fig. 3).
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Overexpression of proteins involved in TNF-α signalling
and B cell survival detected in tear fluid from patients
with pSS
Tear fluid from 11 patients and 11 healthy controls was
analysed using LC-MS, and more than 900 unique pro-
teins were identified with 75,701 peptide spectrum
matches. The application of MS2 TICs using Scaffold,
following proteomic analysis, allowed the identification
of 197 significantly upregulated proteins in tear fluid
from the patient group (Additional file 1: Table S3).
DAVID revealed cellular pathways distinguished from up-
regulated proteins in tear fluid from patients with pSS,
which entail the Pentose phosphate pathway, the tricarb-
oxylic acid/Krebs cycle, and oxidoreductase activity, which
are all elements of metabolism and protein folding (Fig. 1).
By applying STRING analysis we were able to visualise
two protein-protein interaction networks encompassing the
upregulated proteins in tear fluid from patients with pSS;
one is involved in redox-reactions and oxidative stress,
while the other protein-protein network is central in the
formation of the cytoskeleton and cell migration (Fig. 4).
The five most upregulated proteins present in tear fluid
from patients with pSS were DNA (apurinic or apyrimidinic
site) lyase (APEX1), thioredoxin-dependent peroxidase re-
ductase (PRDX3), copine (CPNE1), aconitate hydratase
(ACO2), and LIM domain only protein 7 (LMO7) (Table 5,
Additional file 4: Figure S3). Interestingly, APEX1 is an en-
zyme that is activated in response to oxidative stress, and is
involved in DNA repair and the regulation of transcrip-
tional factors. PRDX3 is an enzyme that regulates NF-
kappa-B activation, and thereby plays a central role in B cell
survival. CPNE1 is a calcium-dependent phospholipid-
binding protein involved in TNF-α receptor signalling, and
in turn in inflammation and apoptosis. ACO2 is an enzyme
of the Krebs cycle with a key role in carbohydrate metabol-
ism. Finally, LMO7 is described as a multifunctional pro-
tein with a central role in cell signalling, cell adhesion, and
ubiquitination (Table 5). Of the five most deviating upregu-
lated proteins in patients with pSS, PRDX3 is present
within the protein network involving redox-reactions and
oxidative stress (Fig. 4).
Additionally, a combined analysis of protein changes
in both stimulated whole saliva and tear fluid was per-
formed using Scaffold in the pSS patient group and the
controls. Out of all the aforementioned proteins in the
study, LCN2 was found to be upregulated in both stimu-
lated whole saliva and tear fluid in patients with pSS.
Low tear fluid volumes were collected individually from
each patient with pSS, leading to fewer than 100 proteins
identified in most of the samples in which EVs were iso-
lated individually from the tear fluid of each participant.
However, on proteomic analysis of EVs extracted from the
pooled tear sample combined from 11 patients with pSS,
CPNE1 and CALM were expressed more in the patient
group. Moreover, the DAVID analysis of the pooled tear
sample revealed cellular pathways involved in calcium-
dependent phospholipid binding, and TNF-α receptor
signalling, both of which are components of the adaptive
immune response and comparable to the calcium ion
binding pathways identified in whole saliva (Fig. 1).
Discussion
By studying the proteome of biological fluids through
LC-MS approaches, and possibly combined with the
Fig. 1 Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis delineating cellular pathways that involve proteins identified in
whole saliva, tear fluid, and extracellular vesicles (EVs). Cellular pathways involving innate and adaptive immune responses, cellular component assembly,
metabolism and protein folding were identified using DAVID (v 6.7, https://david.ncifcrf.gov) analysis for each sample of whole saliva, tear fluid and EVs
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chromatographic separation of extracellular vesicles from
other biomolecules, the search for potential biomarkers
and therapeutic targets can be realised for SS. Such bio-
markers can in turn be implemented as potential non-
invasive diagnostic tools that can be applied for monitor-
ing disease progression. The majority of proteomic studies
of SS have been based on saliva as the biological fluid,
using different mass spectrometry approaches, in addition
Fig. 2 Protein-protein interaction networks of upregulated proteins associated with primary Sjögren’s syndrome identified in stimulated whole saliva.
Two distinct protein-protein interaction networks are visualised. One is involved in metabolism and redox reactions, while the other plays a central
role in both innate and adaptive immunity and contains the most upregulated protein in the patient group, namely neutrophil gelatinase-associated
lipocalin (LCN2). The five most upregulated proteins in the patient group (Table 3) are indicated with red circles. The Search Tool for the Retrieval of
Interacting Genes/Proteins (http://string-db.org/) was used to generate the networks, where potential interactions of proteins with medium confidence
are shown. The different clusters are indicated by the same colour. The colour of the connecting lines indicates the type of evidence used in predicting
the associations (red gene fusion, yellow text-mining extracted from literature, purple protein-protein interaction datasets, light blue protein interaction
groups, black linked across species). CALM calmodulin, CALML5 calmodulin-like protein 5, GRN granulin adipocyte plasma, APMAP
membrane-associated protein, GNA13 guanine nucleotide-binding protein subunit alpha-13, WDR1 WD repeat-containing protein 1,
SIRPA tyrosine-protein phosphatase non-receptor type substrate 1, LSP1 lymphocyte-specific protein 1
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to genomics [14, 16–21]. This confirms that saliva not
only reflects the salivary gland involvement that charac-
terises the disease process in SS [18, 24, 25], but addition-
ally has the potential to communicate an individual’s
current health [26, 27].
So far tear fluid has only been used to identify potential
biomarkers for pSS in a limited number of proteomic
studies [22, 23]. Hence, in the current study we hypothe-
sised that by applying LC-MS alone, and in combination
with size-exclusion chromatography of both stimulated
whole saliva and tear fluid collected from patients with
pSS and from healthy controls, novel biomarkers encom-
passing both salivary and lacrimal disease target organs
could possibly be identified.
In order to delineate cellular pathways involving the up-
regulated proteins identified with LC-MS in the samples
from the patients with pSS, GO and Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway overrepresenta-
tion analyses using DAVID were performed. Our results
demonstrated pathways of the adaptive immune response
in the whole saliva, of the cellular component assembly in
the EVs extracted from whole saliva, of metabolism and
protein folding in the tear fluid of patients with pSS and
finally, components of the adaptive immune response in
the EVs isolated from the pooled sample of tear fluid from
patients with pSS, which was comparable to the calcium
ion binding pathways identified in whole saliva (Fig. 1).
Viewed as a whole, the identified cellular pathways and
components clearly indicate the involvement of auto-
immune reactions and over-activation of the adaptive and
innate immune systems in patients with pSS, both as a
consequence of disease pathogenesis and probably also as
part of the healing process.
The LC-MS analyses indicate upregulation of proteins
involved in innate immunity, cell signalling and wound
repair in whole saliva from patients with pSS. Interest-
ingly, LCN2, the most upregulated protein in whole sal-
iva from patients with pSS, is an iron-binding protein
involved in the innate immune system, and is particu-
larly responsible for the activation of neutrophils [50].
This suggests the involvement of viral infection in SS
pathogenesis. A similar implication was depicted by Hu
and co-workers [18], where they identified salivary prote-
omic and genomic biomarkers for SS showing upregula-
tion of genes involved in the IFN pathway, thereby
suggesting a potential role for viral infection in SS. More-
over, both GRN, a cytokine-like peptide that is central in
inflammation due to its active role in wound repair and
tissue remodelling [51], and CALML5, a calcium-binding
protein that plays a central role in the differentiation of
keratinocytes [52], were also upregulated in our patient
group. This finding in turn provides evidence of acinar
damage and oral environment alteration.
Both Giusti et al. [13] and Fleissig et al. [19] identified
biomarkers that might include specific indication of tissue
damage (e.g. actin), inflammation (e.g. calgranulins), and
tissue repair (e.g. keratin 6 L) in unstimulated whole saliva.
The present study identified similar potential with GRN
and CALML5 in stimulated whole saliva (Table 3,
Additional file 2: Figure S1). Furthermore, CALM, a
calcium-binding protein that plays a role in intracellular
signalling, and ESP1, a cholesterol transporter involved in
cholesterol homeostasis within the endosome and/or lyso-
some, were also upregulated in whole saliva from patients
with pSS. Similarly, previous proteomic studies on whole
saliva have determined broad and distinct protein patterns
that are characteristic of SS, including secretory proteins,
enzymes, highly abundant immune system-related mole-
cules (e.g. β2-microglobulin), and cytokines such as IL-4
and IL-5 [21, 28, 29]. The current STRING analysis of
whole saliva also strengthens the concept of involvement
and over-activation of the innate and adaptive immune sys-
tem in SS. This is presumably due to the upregulation of
LCN2 and other related pro-inflammatory-related proteins
in the patients with pSS to form protein-protein network
interactions (Fig. 2).
Using size exclusion chromatography on whole saliva to
isolate EVs followed by LC-MS allowed us to identify poten-
tial biomarkers that are vital for activation of the innate im-
mune system and adipocyte differentiation. More precisely,
Table 3 Highly upregulated proteins in stimulated whole saliva from patients with pSS





1 LCN2 Neutrophil gelatinase-associated
lipocalin
10 : 2 38 : 2 Iron-binding protein; innate immunity (neutrophils)
2 GRN Granulins 7 : 0 12 : 0 Cytokine-like peptide; inflammation, wound repair, tissue
remodelling
3 CALM Calmodulin 7 : 1 17 : 1 Calcium-binding protein; intracellular signalling
4 NPC2 Epididymal secretory protein 1 6 : 0 11 : 0 Cholesterol transporter; cholesterol homeostasis
(endosome/lysosome)
5 CALML5 Calmodulin-like protein 5 5 : 0 13 : 0 Calcium-binding protein; differentiation of keratinocytes
aThe five most upregulated proteins in whole saliva from patients with primary Sjögren’s syndrome (pSS) deviating in replicates, i.e. number of individuals
(frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/). bThe
classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org). C controls
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the most upregulated protein in EVs from whole saliva,
namely APMAP, is an enzyme central to adipocyte develop-
ment. We have recently shown increased occurrence of
adipose tissue replacement in minor salivary gland biopsies
from patients with SS [53]. Interestingly, these adipocytes
were detected in areas rich in IL-6, suggesting their active
involvement in immune reactions. Hence, the upregulation
of APMAP in stimulated whole saliva could be an indication
of adipocyte involvement in disease progression. More-
over, both GNA13, a G-protein that consequently plays
a role in transmembrane signalling, and WDR1, a
regulatory protein involved in the disassembly of actin
filaments, are proteins needed to drive inflammation
and tissue damage, respectively.
Interestingly, SIRPA is another potential biomarker of
the pro-inflammatory process, as it regulates NK cells and
dendritic cells. Furthermore, LSP1, being involved in
innate immunity, specifically neutrophil activation and
chemotaxis, is another possible indicator of the involve-
ment of viral infection in the pathogenesis of SS (Table 4,
Additional file 3: Figure S2). One major protein-protein
interacting network was identified for EVs isolated from
Fig. 3 Protein-protein interaction networks of upregulated proteins associated with primary Sjögren’s syndrome detected in extracellular vesicles from whole
saliva. One major protein-protein interaction network is visualised. The proteins identified are involved in the cytoskeleton, in addition to cell migration and
cell junction. Out of the five most upregulated proteins in pSS (Table 4), indicated with red circles, both guanine nucleotide-binding protein subunit alpha-13
(GNA13) and WD repeat-containing protein 1 (WDR1) are present within this protein network. The Search Tool for the Retrieval of Interacting Genes/Proteins
(http://string-db.org/) was used to generate the networks, where potential interactions of proteins with medium confidence are shown. The different clusters
are indicated by the same colour. The colour of the connecting lines indicates the type of evidence used in predicting the associations (red gene fusion, yellow
text-mining extracted from literature, purple protein-protein interaction datasets, light blue protein interaction groups, black linked across species). APMAP
membrane-associated protein, SIRPA tyrosine-protein phosphatase non-receptor type substrate 1, LSP1 lymphocyte-specific protein 1
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Table 4 Highly upregulated proteins in EVs isolated from stimulated whole saliva from patients with pSS





1 APMAP Adipocyte plasma membrane-associated
protein
7 : 0 26 : 0 Enzyme; adipocyte differentiation
2 GNA13 Guanine nucleotide-binding protein
subunit alpha-13
6 : 0 11 : 0 G-protein; transmembrane signalling
3 WDR1 WD repeat-containing protein 1 6 : 0 11 : 0 Regulatory protein; disassembly of
actin filaments
4 SIRPA Tyrosine-protein phosphatase
non-receptor type substrate 1 (PTPN1)
6 : 0 9 : 0 Glycoprotein; innate immunity
(NK cells), dendritic cell inhibition
5 LSP1 Lymphocyte-specific protein 1 5 : 0 9 : 0 Actin-binding protein; neutrophil
activation, chemotaxis
aThe five most upregulated proteins in extracellular vesicles isolated from whole saliva from patients with primary Sjögren’s syndrome (pSS) deviating in
replicates, i.e. number of individuals (frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://
www.proteomesoftware.com/products/scaffold/). bClassification and functions of the proteins presented were identified using publicly available databases, such as
UniProt (http://www.uniprot.org). C controls, NK natural killer
Fig. 4 Protein-protein interaction networks of upregulated proteins associated with primary Sjögren’s syndrome detected in tear fluid. Two
protein-protein interaction networks are visualised. One is central in the formation of the cytoskeleton and cell migration, while the other is
involved in redox reactions and oxidative stress and contains one out of the five most upregulated proteins, as indicated with red circles (Table 5),
namely thioredoxin-dependent peroxidase reductase (PRDX3). The Search Tool for the Retrieval of Interacting Genes/Proteins (http://string-db.org/
) was used to generate the networks, where potential interactions of proteins with medium confidence are shown. The different clusters are
indicated by the same colour. The colour of the connecting lines indicates the type of evidence used in predicting the associations (red gene
fusion, yellow text-mining extracted from literature, purple protein-protein interaction datasets, light blue protein interaction groups, black linked
across species). APEX1 DNA (apurinic or apyrimidinic site) lyase, CPNE1 copine, ACO2 aconitate hydratase, LMO7 LIM domain only protein 7
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whole saliva, including proteins that regulate the forma-
tion and disassembly of the cytoskeleton, in addition to
their involvement in cell migration and cell junction. Both
GNA13 and WDR1 were present within this protein
network (Fig. 3).
As only a limited number of proteomic studies have so
far been performed on tear fluid from patients with SS [22,
23], we were interested in analysing tear fluid collected
from patients with pSS and healthy controls, in combin-
ation with whole saliva from the same individuals, in order
to explore novel biomarkers encompassing both lacrimal
and salivary disease target organs. We identified overex-
pression of proteins involved in TNF-α signalling (CPNE1)
and B cell survival (PRDX3), in the Krebs cycle (ACO2)
and in oxidative stress (APEX1) in tear fluid from patients
with pSS (Table 5, Additional file 4: Figure S3). Moreover,
two protein-protein interaction networks encompassing the
upregulated proteins in tear fluid from patients with pSS
were visualised using STRING. These networks were
involved in oxidative stress, and the formation of the cyto-
skeleton and cell migration, respectively. With a vital role
in regulating NF-κ B activation, and in turn B cell survival,
PRDX3 was present within the protein network involving
redox reactions and oxidative stress (Fig. 4).
Additionally, we explored protein expression in whole
saliva and tear fluid simultaneously, and out of all the
aforementioned proteins in the study, LCN2 was found to
be upregulated in both fluids in the patients with pSS.
Hence, the most upregulated protein in whole saliva from
patients with pSS identified in our current analysis
(Table 3), is also a key player in tear fluid from these same
individuals. Being an iron-binding protein involved in the
innate immune system and the activation of neutrophils
[50], LCN2 could be viewed as a possible biomarker for
SS, whereby screening for LCN2 in whole saliva and tear
fluid from patients with pSS could provide additional
diagnostic accuracy. This observation further strengthens
the notion of a role for viral infection in the pathogenesis
of SS. Interestingly, LCN2 has also been previously
proposed as a potential disease biomarker in the auto-
immune disease systemic lupus erythematosus (SLE), as
elevated levels of anti-LCN2 were detected in serum
samples from patients with SLE [54].
In spite of low tear fluid volumes collected individually
from each patient with pSS, leading to few attainable data
from the EVs isolated individually from each participant,
our proteomic analysis of EVs extracted from the pooled
tear sample combined from 11 patients with pSS revealed
that CPNE1 and CALM were expressed more in the patient
group. The presence of both these upregulated proteins in-
dicates how their cellular functions fulfil each other, with
CPNE1 playing a central role in inflammation and apop-
tosis due to TNF-α signalling, while CALM is essential in
cell signaling and the activation of the immune system.
Conclusions
In conclusion, the application of LC-MS alone and in
combination with size-exclusion chromatography, to both
stimulated whole saliva and tear fluid from patients with
pSS, allowed the isolation of EVs and the screening for
novel biomarkers encompassing both salivary and lacrimal
disease target organs. These biomarkers include LCN2,
APMAP and CPNE1. The screening for such biomarkers in
whole saliva and tear fluid from patients with pSS as a part
of the diagnostic process could provide additional diagnos-
tic accuracy. Furthermore, saliva and tear fluid represent
attractive mediums for diagnosis using proteomic analysis,
as collection of these samples is not invasive, their compos-
ition is not complex and the analysis may be easily repeated
for monitoring the disease over time. As a next step, the
validation of these biomarkers in larger SS cohorts is
needed, whereby disease stratification can be explored in
relation to protein expression levels. It is also of interest to
validate these biomarkers in related diseases such as sicca
syndrome and secondary SS. By doing so, one can explore
whether these biomarkers can also be applied to monitor
disease progression, and thereafter explore more strategic
targeted therapeutic approaches in SS.
Table 5 Highly upregulated proteins in tear fluid from patients with pSS





1 APEX1 DNA-(apurinic or apyrimidinic site)
lyase
10 : 1 22 : 1 Enzyme; oxidative stress, DNA repair,
regulation of transcriptional factors
2 PRDX3 Thioredoxin-dependent peroxidase
reductase
8 : 0 15 : 0 Enzyme; redox regulation, regulates NF-kappa-B
activation (B cell survival)
3 CPNE1 Copine 1 9 : 2 23 : 2 Phospholipid-binding protein (calcium-dependent),
TNF-α receptor signalling
4 ACO2 Aconitate hydratase 7 :0 19 : 0 Enzyme; tricarboxylic acid cycle/Krebs cycle,
carbohydrate metabolism
5 LMO7 LIM domain only protein 7 7 : 0 9 : 0 Cell signalling, cell adhesion, ubiquitination
aThe five most upregulated proteins in tear fluid from patients with primary Sjögren’s syndrome (pSS) deviating in replicates, i.e. number of individuals
(frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/). bClassification
and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org) C controls
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Additional files
Additional file 1: Table S1. Upregulated proteins in whole saliva from
patients with pSS. Table S2. Upregulated proteins in EVs isolated from
whole saliva from patients with pSS. Table S3. Upregulated proteins in
tear fluid from patients with pSS (DOC 348 kb)
Additional file 2: Figure S1. Spectral count representation of highly
upregulated pSS-associated proteins identified in stimulated whole saliva.
Spectral counts from individual stimulated whole saliva samples from
patients with pSS (black circles) and controls (white circles) showing little
or none of the proteins LCN2, GRN, CALM, NPC2 and CALML5 in controls
compared to patients with pSS (TIF 8483 kb)
Additional file 3: Figure S2. Spectral count representation of highly
upregulated pSS-associated proteins detected in EVs from whole saliva.
Spectral counts from individual EV samples isolated from whole saliva
from patients with pSS (black circles) and controls (white circles) showing
little or none of the proteins APMAP, GNA13, WDR1, SIRPA and LSP1 in
controls compared to patients with pSS (TIF 8483 kb)
Additional file 4: Figure S3. Spectral count representation of highly
upregulated pSS-associated proteins identified in tear fluid. Spectral
counts from individual tear samples of patients with pSS (black circles)
and controls (white circles) showing little or none of the proteins APEX1,
PRDX3, CPNE1, ACO2 and LMO7 in controls compared to patients with
pSS (TIF 8483 kb)
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